Research programme: hERG potassium channel agonists - PfizerAlternative Names: PD-118057
Latest Information Update: 20 Sep 2011
At a glance
- Originator Pfizer
- Mechanism of Action Potassium channel agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 21 Dec 2005 Preclinical trials in Arrhythmias in USA (unspecified route)